The Phase III Purpose 2 trial compared the safety and efficacy of twice-yearly subcutaneous lenacapavir for pre-exposure ...

Following the promising multicentre, international Purpose 1 and Purpose 2 clinical trials with lenacapavir for HIV ...

Health experts say lenacapavir could reduce the number of global HIV infections significantly. It can protect against HIV ...

According to a study published in the New England Journal of Medicine, twice-yearly injection of Lenacapavir offers a 96 percent ...

Dan O’Day drives Gilead's mission to end HIV worldwide, pioneering treatments like lenacapavir and championing global health ...

Gilead (GILD) announced The New England Journal of Medicine, or NEJM, published the full results from the company’s pivotal ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced The New England Journal of Medicine (NEJM) published the full results ...

Twice-yearly subcutaneous lenacapavir has been shown to be efficacious for prevention of HIV infection in cisgender women. The efficacy of lenacapavir for preexposure prophylaxis (PrEP) in ...

The use of lenacapavir for the prevention of HIV is investigational and has not been determined to be safe or efficacious and is not approved anywhere globally. About Gilead HIV For more than 35 ...

An update from the PURPOSE 2 trial focused on adherence and pharmacokinetics data for lenacapavir, used to prevent HIV.

A vaccination with the drug lenacapavir offers an effective protection against a HIV infection, according to newly published ...